The C17orf100 Knockout HeLa Polyclonal Cells product consists of a polyclonal population of HeLa cells genetically edited using CRISPR/Cas9 to disrupt the endogenous C17orf100 locus. This polyclonal format avoids single-cell cloning, yielding a heterogeneous pool that collectively eliminates C17orf100 protein expression, making it ideal for loss-of-function studies where clonal variation is acceptable. The pool can be expanded directly, ensuring versatility for high-throughput or preliminary analyses.
HeLa cells, originally derived from a cervical adenocarcinoma, are one of the most extensively studied human cell lines. They persistently carry human papillomavirus type 18 (HPV18) genomic sequences, resulting in the stable expression of the E6 and E7 oncoproteins. E6 facilitates the ubiquitination and proteasomal degradation of the tumor suppressor p53, while E7 binds and inactivates the retinoblastoma protein (Rb), leading to unscheduled cell-cycle progression and genomic instability. This well-characterized transformation background makes HeLa cells a powerful platform for investigating candidate cancer genes.
The C17orf100 gene, located on chromosome 17, encodes a protein containing predicted transmembrane domains, suggesting membrane integration or association. Despite its conservation, the biological role of C17orf100 remains elusive; no validated upstream regulators, downstream effectors, or protein?Cprotein interactions have been reported. The gene is not associated with any known human disease, and its expression profile hints at involvement in spermatogenesis, though this function has not been confirmed in somatic cells. Consequently, disrupting C17orf100 in HeLa cells provides a clean system to interrogate potential roles in cellular processes such as adhesion, proliferation, or transmembrane signaling.
In the context of HeLa cells, where the p53 and Rb tumor suppressor axes are already suppressed, investigating C17orf100 loss allows researchers to examine its influence on additional oncogenic mechanisms. The HPV-mediated transformation primes HeLa cells for rapid growth and altered adhesion, making them a sensitive backdrop for detecting subtle phenotypic changes upon gene knockout. This model can reveal whether C17orf100 contributes to processes like anoikis resistance, collective migration, or metabolic reprogramming in cervical cancer cells. Moreover, it facilitates direct comparisons with normal or other cancerous cell lines to determine tissue-specific or transformation-dependent functions.
Researchers can deploy these cells in a broad array of assays. Western blotting and RT-qPCR confirm knockout and gauge transcriptional perturbations, while immunofluorescence microscopy defines subcellular changes. Proliferation and migration assays quantitatively measure growth and motility, respectively, providing direct functional readouts. Beyond these, the polyclonal pool can be used in adhesion assays, invasion studies, or drug sensitivity screens to uncover synthetic lethality interactions. The cells also serve as a foundational material for generating monoclonal knockout lines by limiting dilution. For further guidance or collaborative inquiries, please reach out to the scientific support team at Ascent Research.
